ArticleBiomarker insights2007
A list of candidate cancer biomarkers for targeted proteomics.
Article in Biomarker insights, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 149 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
149 citing papers in PubMed, 1 synthesis or guideline pooled it.
- An original study assessing biomarker success rate in breast cancer recurrence biomarker research.BMC medicine · 2024Pooled it
- A Catalogue of Altered Salivary Proteins Secondary to Invasive Ductal Carcinoma: A Novel In Vivo Paradigm to Assess Breast Cancer Progression.Scientific reports · 2016Trial
- Boronic acid affinity media conjugating with PEG enable precise pH-responsive HPLC separation of glycoproteins depending on differences of sugar chains.Scientific reports · 2026Article
- Evolving stratification and biomarker discovery in cancer research with technological advancement of proteomics: 35 years and counting.Bioscience reports · 2025Review
- Single-Molecule Enzyme Activity Analysis for Illuminating Pathological Proteoforms.ACS central science · 2025Review
- Assessing the translation of diagnostic colorectal cancer biomarkers from bench to bedside.Frontiers in medicine · 2025Article
- Identification of activity-based biomarkers for early-stage pancreatic tumors in blood using single-molecule enzyme activity screening.Cell reports methods · 2024Article
- An Inflection Point in Cancer Protein Biomarkers: What was and What's Next.Molecular & cellular proteomics : MCP · 2023Article
- Exploiting Blood Transport Proteins as Carborane Supramolecular Vehicles for Boron Neutron Capture Therapy.Nanomaterials (Basel, Switzerland) · 2023Article
- Development of fluorogenic substrates for colorectal tumor-related neuropeptidases for activity-based diagnosis.Chemical science · 2023Article
- Transcriptomic analysis of pancreatic adenocarcinoma specimens obtained from Black and White patients.PloS one · 2023Article
- Unlocking the power of nanomedicine: the future of nutraceuticals in oncology treatment.Frontiers in nutrition · 2023Review
- Construction of 2DE Patterns of Plasma Proteins: Aspect of Potential Tumor Markers.International journal of molecular sciences · 2022Article
- Modeling and integration of N-glycan biomarkers in a comprehensive biomarker data model.Glycobiology · 2022Article
- Metabolite biomarker discovery for human gastric cancer using dried blood spot mass spectrometry metabolomic approach.Scientific reports · 2022Article
- Label-Free Imaging of Single Proteins and Binding Kinetics Using Total Internal Reflection-Based Evanescent Scattering Microscopy.Analytical chemistry · 2022Article
- Use of MS-GUIDE for identification of protein biomarkers for risk stratification of patients with prostate cancer.Clinical proteomics · 2022Article
- Relevant proteins for the monitoring of engraftment phases after allogeneic hematopoietic stem cell transplantation.Clinics (Sao Paulo, Brazil) · 2022Article
- Protein detection in blood with single-molecule imaging.Science advances · 2021Article
- Article
89 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We have compiled from literature and other sources a list of 1261 proteins believed to be differentially expressed in human cancer. These proteins, only some of which have been detected in plasma to date, represent a population of candidate plasma biomarkers that could be useful in early cancer detection and monitoring given sufficiently sensitive specific assays. We have begun to prioritize these markers for future validation by frequency of literature citations, both total and as a function of time. The candidates include proteins involved in oncogenesis, angiogenesis, development, differentiation, proliferation, apoptosis, hematopoiesis, immune and hormonal responses, cell signaling, nucleotide function, hydrolysis, cellular homing, cell cycle and structure, the acute phase response and hormonal control. Many have been detected in studies of tissue or nuclear components; nevertheless we hypothesize that most if not all should be present in plasma at some level. Of the 1261 candidates only 9 have been approved as "tumor associated antigens" by the FDA. We propose that systematic collection and large-scale validation of candidate biomarkers would fill the gap currently existing between basic research and clinical use of advanced diagnostics.
Indexed as
Identifiers
19690635PMC2716785What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.